Neurorx Research
Neurorx Research is recorded as a service provider in 47 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 47 trials · Latest update first
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
Sponsor Genzyme Corp.
- Start (EU)
- Latest update
- Estimated end
An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Sponsor Zenas Biopharma (USA) LLC
- Start (EU)
- Latest update
- Estimated end
A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-center, phase 1/2 study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with Relapsing Multiple Sclerosis with breakthrough disease activity during previous treatment with a highly efficacious therapy
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-center, phase I/II study to assess safety, disease progression, and cellular kinetics following YTB323 administration in participants with non-active Progressive Multiple Sclerosis (PMS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Single Ascending Doses of TRCN-1023 Administered by Intrathecal Injections to Adult People Living with Amyotrophic Lateral Sclerosis
Sponsor Trace Neuroscience Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT - physician’s choice in the treatment of newly diagnosed RMS (STHENOS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- The trial enrolled 185 participants at 41 centres across Germany, France, Italy, and Spain.
- A 2022 protocol amendment enlarged the eligible population, reduced protocol complexity, and revised eligibility criteria to align with current ofatumumab and other DMT product information.
- A 2021 protocol amendment required full routine laboratory testing at every on-site visit from baseline through Month 15.
These findings describe the trial, not the service provider’s performance or responsibility.
Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS)
Sponsor Tg Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early-Stage Parkinson’s Disease
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A two-year, double-blind, randomized, multicenter, active-controlled Core Phase study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly in pediatric patients with multiple sclerosis with five-year fingolimod Extension Phase
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients with Relapsing Multiple Sclerosis
Sponsor Zenas Biopharma (USA) LLC
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sclerosis
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A randomized, Phase 3, open-label study to investigate pharmacokinetics, safety, and efficacy of subcutaneous compared to intravenous frexalimab in adult participants with multiple sclerosis.
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Neurorx Research?
The 2026-10-09 snapshot links Neurorx Research to 47 distinct CTIS trials. Recorded services include Laboratory services, Central Medical Reading or Imaging Reading, Medical expertise, Central imaging, among 25 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Neurorx Research?
The most frequently recorded therapeutic areas are Neurology, Immunology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Neurorx Research conducted?
The linked trials record locations in 26 countries, including Spain, Italy, Poland, Germany, France. These are trial locations, not confirmed office locations or countries where Neurorx Research delivered services.
What can this page tell me about Neurorx Research's trial experience?
Browse 47 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Neurorx Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Neurorx Research Inc.